Bragar Eagel & Squire, P.C. Reminds Investors of Cytokinetics, Quanex, RCI, and Fortinet to Contact the Firm About their Rights

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Cytokinetics, Incorporated (NASDAQ:CYTK), Quanex Building Products Corporation (NYSE:NX), RCI Hospitality Holdings, Inc. (NASDAQ:RICK), and Fortinet, Inc. (NASDAQ:FTNT). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Cytokinetics, Incorporated (NASDAQ: CYTK)

Class Period: December 27, 2023 to May 6, 2025 Lead Plaintiff Deadline: November 17, 2025 According to the complaint, defendants made materially false and misleading statements regarding the timeline for the New Drug Application (“NDA”) submission and approval process for aficamten. Specifically, defendants represented that the Company expected approval from the U.S. Food and Drug Administration (“FDA”) for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date, and failed to disclose material risks related to the Company’s failure to submit a Risk Evaluation and Mitigation Strategy (“REMS”) that could delay the regulatory process. On May 6, 2025, during an earnings call, it was revealed that the Company had multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials. This confirmed defendants’ awareness of potential REMS requirements and their reckless decision to omit it from the initial submission, misleading investors about the regulatory timeline. As a result of defendants’ false and misleading statements, class members purchased Cytokinetics’ common stock at artificially inflated prices and suffered significant losses when the truth was revealed. For more information on the Cytokinetics lawsuit go to: https://bespc.com/cases/CYTK

Quanex Building Products Corporation (NYSE: NX)

Class Period: December 12, 2024 to September 5, 2025 Lead Plaintiff Deadline: November 18, 2025 The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) the Company’s procedures and policies regarding tooling and equipment maintenance in its Tyman Mexico facility were significantly “underinvested”; (2) as a result, the Company’s tooling and equipment conditions had significantly degraded to near “catastrophic” levels; (3) that, as a result of the foregoing, the Company was likely to incur significant costs, “pushing out the timing” of expected benefits from the Tyman integration; (4) that Quanex had previously identified the foregoing issues; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. For more information on the Quanex lawsuit go to: https://bespc.com/cases/NX

RCI Hospitality Holdings, Inc. (NASDAQ: RICK)

Class Period: December 15, 2021 to September 16, 2025 Lead Plaintiff Deadline: November 20, 2025 According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Defendants engaged in tax fraud; (2) Defendants committed bribery to cover up the fact that they committed tax fraud; (3) as a result, defendants understated the legal risk facing the company; and (4) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. For more information on the RCI lawsuit go to: https://bespc.com/cases/RICK

Fortinet, Inc. (NASDAQ: FTNT)

Class Period: November 8, 2024 to August 6, 2025 Lead Plaintiff Deadline: November 21, 2025 The Fortinet class action lawsuit alleges that: (i) defendants knew that the refresh cycle would never be as lucrative as they represented, nor could it, because it consisted of old products that were a "small percentage" of Fortinet's business; (ii) defendants misrepresented and concealed that they did not have a clear picture of the true number of FortiGate firewalls that could be upgraded; and (iii) while telling investors that the refresh would gain momentum over the course of two years, Fortinet misrepresented and concealed that it had aggressively pushed through roughly half of the refresh in a period of months, by the end of the second quarter of 2025. The Fortinet class action lawsuit further alleges that on August 6, 2025, Fortinet revealed during its earnings call that Fortinet was already "approximately 40% to 50% of the way through the 2026 upgrade cycle at the end of the second quarter [of 2025]." The complaint also alleges that defendants: (i) admitted that "it's hard[] for us to predict" the total number of FortiGates requiring an upgrade; (ii) suggested customers had "excess [firewall] capacity from [purchasing firewalls in] prior years" and therefore did not need to upgrade; and (iii) revealed that the refresh could not have had "much business impact" as it consisted of only a "small percentage" of Fortinet's business because the products were "12 to 15 years" old and had been sold at a time when Fortinet's business was 5-10 times smaller, meaning that the total number of FortiGates eligible for an upgrade was inherently limited. On this news, the price of Fortinet common stock fell more than 22%, according to the complaint. For more information on the Fortinet lawsuit go to: https://bespc.com/cases/FTNT

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
[email protected]
www.bespc.com